Gilead Sciences (NASDAQ:GILD) reported quarterly losses of $(6.75) per share which beat the analyst consensus estimate of $(7.24) by 6.64 percent. This is a 435.82 percent decrease over earnings of $2.01 per share from the same period last year. The company reported quarterly sales of $7.803 billion which beat the analyst consensus estimate of $7.400 billion by 5.45 percent. This is a 10.18 percent increase over sales of $7.082 billion the same period last year.